69 related articles for article (PubMed ID: 16188440)
1. Palmar-plantar erythrodysesthesia due to docetaxel-capecitabine therapy is treated with vitamin E without dose reduction.
Kara IO; Sahin B; Erkisi M
Breast; 2006 Jun; 15(3):414-24. PubMed ID: 16188440
[TBL] [Abstract][Full Text] [Related]
2. Palmar-plantar erythrodysesthesia associated with chemotherapy and its treatment.
Farr KP; Safwat A
Case Rep Oncol; 2011 Apr; 4(1):229-35. PubMed ID: 21537373
[TBL] [Abstract][Full Text] [Related]
3. Penile-scrotal erythrodysesthesia among rectal cancer patients receiving fluoropyrimidine-based chemoradiation: a case report series.
Adames A; O'Brien DR; Kelly AR; Saltz LB; Garcia-Aguilar J; Zinovoy M; Williams V; Wu A; Reyngold M; Hajj C; Crane C; Cercek A; Smith JJ; Markova A; Cuaron J; McCann P; Romesser PB
Int J Colorectal Dis; 2024 May; 39(1):75. PubMed ID: 38780794
[TBL] [Abstract][Full Text] [Related]
4. Capecitabine-Induced Genital Hand-Foot Syndrome Treated With Topical Tacrolimus.
Chan BL; Wang T
Cureus; 2024 Apr; 16(4):e57570. PubMed ID: 38707169
[TBL] [Abstract][Full Text] [Related]
5. A case of palmar-plantar erythrodysesthesia in a lung cancer patient receiving atezolizumab maintenance.
Teymouri F; Dasanu CA
J Oncol Pharm Pract; 2024 May; ():10781552241258175. PubMed ID: 38813782
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of Vitamin E Treatment for Hand-Foot Syndrome in Patients Receiving Capecitabine.
Yamamoto D; Yamamoto C; Iwase S; Kuroda Y; Odagiri H; Nagumo Y
Breast Care (Basel); 2010; 5(6):415-416. PubMed ID: 21494409
[No Abstract] [Full Text] [Related]
7. Management of hand-foot syndrome induced by capecitabine.
Gressett SM; Stanford BL; Hardwicke F
J Oncol Pharm Pract; 2006 Sep; 12(3):131-41. PubMed ID: 17022868
[TBL] [Abstract][Full Text] [Related]
8. Randomized trial of two different doses of pyridoxine in the prevention of capecitabine-associated palmar-plantar erythrodysesthesia.
Chalermchai T; Tantiphlachiva K; Suwanrusme H; Voravud N; Sriuranpong V
Asia Pac J Clin Oncol; 2010 Sep; 6(3):155-60. PubMed ID: 20887495
[TBL] [Abstract][Full Text] [Related]
9. Randomized trial of vitamin B6 for preventing hand-foot syndrome from capecitabine chemotherapy.
Braik T; Yim B; Evans AT; Kassem M; Mullane M; Lad T; Hussein L; Cleveland B; McDunn S
J Community Support Oncol; 2014 Feb; 12(2):65-70. PubMed ID: 24971407
[TBL] [Abstract][Full Text] [Related]
10. Anticancer drug induced palmar plantar erythrodysesthesia.
Palaniappan M; Srinivasamurthy S; Dubashi B; Chandrasekaran A
J Clin Diagn Res; 2014 Oct; 8(10):HC01-3. PubMed ID: 25478366
[TBL] [Abstract][Full Text] [Related]
11. Prevention of palmar-plantar erythrodysesthesia with an antiperspirant in breast cancer patients treated with pegylated liposomal doxorubicin (SAKK 92/08).
Templeton AJ; Ribi K; Surber C; Sun H; Hsu Schmitz SF; Beyeler M; Dietrich D; Borner M; Winkler A; Müller A; von Rohr L; Winterhalder RC; Rochlitz C; von Moos R; Zaman K; Thürlimann BJ; Ruhstaller T;
Breast; 2014 Jun; 23(3):244-9. PubMed ID: 24656636
[TBL] [Abstract][Full Text] [Related]
12. Docetaxel-associated palmar-plantar erythrodysesthesia: a case report and review of the literature.
Harris CS; Wang D; Carulli A
J Oncol Pharm Pract; 2014 Feb; 20(1):73-80. PubMed ID: 23478198
[TBL] [Abstract][Full Text] [Related]
13. Palmar-plantar erythrodysesthesia (PPE): a literature review with commentary on experience in a cancer centre.
Webster-Gandy JD; How C; Harrold K
Eur J Oncol Nurs; 2007 Jul; 11(3):238-46. PubMed ID: 17350337
[TBL] [Abstract][Full Text] [Related]
14. Prevention strategies for chemotherapy-induced hand-foot syndrome: a systematic review and meta-analysis of prospective randomised trials.
Macedo LT; Lima JP; dos Santos LV; Sasse AD
Support Care Cancer; 2014 Jun; 22(6):1585-93. PubMed ID: 24463616
[TBL] [Abstract][Full Text] [Related]
15. Predictors of Hand-Foot Syndrome and Pyridoxine for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Randomized Clinical Trial.
Yap YS; Kwok LL; Syn N; Chay WY; Chia JWK; Tham CK; Wong NS; Lo SK; Dent RA; Tan S; Mok ZY; Koh KX; Toh HC; Koo WH; Loh M; Ng RCH; Choo SP; Soong RCT
JAMA Oncol; 2017 Nov; 3(11):1538-1545. PubMed ID: 28715540
[TBL] [Abstract][Full Text] [Related]
16. Incidence and implications of chemotherapy related hand-foot syndrome.
Nikolaou V; Syrigos K; Saif MW
Expert Opin Drug Saf; 2016 Dec; 15(12):1625-1633. PubMed ID: 27718746
[TBL] [Abstract][Full Text] [Related]
17. Topical heparin as an effective and safe treatment for patients with capecitabine-induced hand-foot syndrome: results of a phase IIA trial supported by proteomic profiling of skin biopsies.
Rodríguez-Garzotto A; Iglesias-Docampo L; Díaz-García CV; Ruppen I; Ximénez-Embún P; Gómez C; Rodríguez-Peralto JL; de Frutos JO; Lopez-Martin JA; Grávalos C; Cortés-Funes H; Agulló-Ortuño MT
Ther Adv Med Oncol; 2022; 14():17588359221086911. PubMed ID: 35356259
[TBL] [Abstract][Full Text] [Related]
18. Henna Application in the Prevention of Capecitabine-Induced Hand-Foot Syndrome in Breast and Colorectal Cancer Patients.
Kayikci EE; Can G; Sen F; Saip P
Florence Nightingale J Nurs; 2020 Oct; 28(3):299-311. PubMed ID: 34263209
[TBL] [Abstract][Full Text] [Related]
19. Liposomal doxorubicin-related palmar-plantar erythrodysesthesia (hand-foot syndrome): a case report.
Ni C; Fang J; Qian H; Xu Q; Shen F
J Int Med Res; 2020 Dec; 48(12):300060520974854. PubMed ID: 33356712
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
